Affordable Access

Publisher Website

Amyloid imaging in Alzheimer's disease

Authors
Journal
Neuropsychologia
0028-3932
Publisher
Elsevier
Publication Date
Volume
46
Issue
6
Identifiers
DOI: 10.1016/j.neuropsychologia.2008.03.020
Keywords
  • Alzheimer'S Disease
  • Mild Cognitive Impairment (Mci)
  • Positron Emission Tomography (Pet)
  • Amyloid
  • Cognition
  • Amyloid Pet Tracers
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Alzheimer's disease (AD) is a complex neurodegenerative disorder of which the exact cause is still not known. There has, however, been remarkable progress in the understanding of the pathophysiological events that underlie the disease with a focus on amyloid formation. We do not know yet if amyloid is the most crucial target for an effective therapy in AD. The new amyloid PET imaging tracer ligands offer possibilities for measuring fibrillar beta amyloid (Aβ) in the brain and for studying the time course of amyloid in the brain. This opens up new possibilities for early diagnosis as well as new tools for monitoring anti-amyloid therapy in AD.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

PET imaging of amyloid in Alzheimer's disease

on The Lancet Neurology Jan 01, 2004

Amyloid imaging in Alzheimer's disease.

on Current Opinion in Neurology August 2007

Clinical amyloid imaging in Alzheimer's disease.

on The Lancet Neurology Jul 01, 2011

PET imaging of amyloid in Alzheimer's disease.

on The Lancet Neurology September 2004
More articles like this..